Clinical Trial: A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

Study Status: Temporarily not available
Recruit Status: Temporarily not available
Study Type: Expanded Access

Official Title: A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

Brief Summary: This is an expanded access protocol/compassionate use single institution study designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with progressive neuroblastoma and metastatic pheochromocytoma who are not eligible for therapies of higher priority. Response rate, toxicity, and time to progression and death will be evaluated.

Detailed Summary:
Sponsor: Northwell Health

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Northwell Health

Dates:
Date Received: January 5, 2017
Date Started:
Date Completion:
Last Updated: January 9, 2017
Last Verified: January 2017